WELLESLEY HILLS, Massachusetts, June 8 /PRNewswire/ --

Joseph F. Finn, Jr., C.P.A. (Finn) announced today that he has received a statement from Ludwig Institute of Cancer Research Ltd., Brussels Branch. The statement is quoted in its entirety below.

Prospect Therapeutics' lead product candidate, GCS-100, is a carbohydrate molecule which inhibits the activity of Galectin-3, a protein found in high concentration in a broad range of human cancers. Prospect reported that GCS-100 could induce apoptosis of cancer cells and that clinical trial results indicated that reduction in leukemic cell number could be obtained without severe side effects.

HAIFA, Israel, June 8 /PRNewswire/ --

- ORL Succeeds in Reducing Cost From Original $670 Million by Leveraging Macro-Economic Environment Unit, due to be Operational by Early 2012, is Expected to Process 25,000 Barrels per day Unit Expected to Increase ORL's Nelson Complexity Index From Current 7.4 to 9.0

HAIFA, Israel, June 8 /PRNewswire/ --

BOSTON and CAMBRIDGE, England, June 8 /PRNewswire/ --

- New EM300 Series first ZigBee system-on-chips (SoCs) based on the 32-bit ARM Cortex-M3 processor

Ember, a leader in wireless networking technology, today unveiled the EM300 Series, its next-generation ZigBee chip family that packs the industry's highest wireless networking performance and application code space into the lowest power-consuming chip set.

HELSINKI, June 8 /PRNewswire/ -- Ipsat Therapies announced today that oral P1A beta-lactamase met all end-points and provided protection for the normal gastrointestinal microflora in a phase 1 study in healthy subjects receiving intravenous piperacillin/tazobactam for 5 days.

Ipsat P1A

P1A is the most advanced of Ipsat's portfolio of beta-lactamases. It is administered orally and designed to inactivate the residual amounts of certain beta-lactam antibiotics excreted into the patients' gastrointestinal tract, after intravenous administration of these antibiotics for serious infections, and to reduce the transmission of resistant bacteria.

The Phase I study,

PARIS, June 8 /PRNewswire/ --

- Survey Reveals Most Europeans Know so Little About Parkinson's They Would be Unlikely to Recognise its Early Symptoms and See Their Doctor for Prompt Diagnosis and Treatment

NOORDIJK, The Netherlands, June 8 /PRNewswire/ --

- Novel Mobile Service AllAroundMe Uses Smart Navigation Technology to Provide Personalised Information on Shopping, Dining and Events - Wherever you are

With its novel mobile phone service AllAroundMe, launched in The Netherlands on 8 June, Dutch company Mobzili provides location-based information on shopping, entertainment, tourism and public transportation by combining satellite and telecommunication technology with the latest and greatest local information. AllAroundMe technology development was supported by the European Space Agency (ESA) Technology Transfer Programme Office through its Business Incubation Centre in Noordwijk, The Netherlands.

MILTON KEYNES, England, June 8 /PRNewswire/ -- SPEKTOR(R) Forensic Intelligence, a fast and forensically sound data acquisition, analysis and review solution for front line officers from the law enforcement and government communities, has been launched by UK-based forensic computing experts Evidence Talks Ltd.

The portable, easy to use system enables officers with minimal training to preserve data and make informed decisions while ensuring evidential continuity, along with forensic and legal acceptability.

CONSHOHOCKEN, Pennsylvania, June 8 /PRNewswire/ --

Conshohocken-based Quaker Chemical Corporation, a leading global provider of process chemicals, today announced the launch of the new QUINTOLUBRIC(R) website, www.quintolubric.com, to better meet the needs of their customers. The new site has been redesigned with a clearer structure and simplified, user-friendly navigation that makes finding information easier than before. The site also has a totally new graphic look.

LONDON, June 8 /PRNewswire/ -- Survey Shows Many Doctors Find the Management of Atrial Fibrillation Difficult and Patients are Unaware of the Risks, Complexities and Treatment for This Most Common of Heart Rhythm Disorders

Four leading patient and medical associations announced today the formation of AF AWARE (Atrial Fibrillation AWareness And Risk Education), a joint initiative to highlight and address issues that contribute to the growing burden of atrial fibrillation (AF) worldwide.

AF is a common yet under-recognised and poorly understood abnormal heart rhythm that is associated with poor quality of life, substantial numbers of hospitalisations, increased risk of severe and potentially fatal cardiovascular complications such as stroke, as well as death.

BRUSSELS, June 8 /PRNewswire/ -- The 'Excellence in Epilepsy' Journalism Award - an initiative of the International Bureau for Epilepsy (IBE) and UCB - invites journalists from around the world to submit stimulating, informed and compelling news and feature stories on epilepsy.

The award seeks to increase awareness and improve understanding of epilepsy. The closing date for entries and nominations is 30 June, 2009.

To view the Multimedia News Release, please click:

http://www.prnewswire.com/mnr/ucb/36384/